Notogen, Inc. has discovered a significant regenerative medicine treatment addressing spinal disc degeneration which is strongly associated with back pain. Lower Back Pain is the number one musculoskeletal disorder worldwide affecting up to 80% of people such that they require medical assistance and costing between $100-200billion per year. Notogen’s first therapeutic product targeting Degenerative Disc Disease (DDD) is based on 18+ years of clinical and laboratory research into back/neck pain. The product is an injectable solution that is faster to administer, more cost-effective, and less invasive to the patient than existing implant or biologic offerings. The company is headquartered in San Diego CA with the research facility located in JLabs, Toronto, Canada and has secured funding for initial manufacturing and regulatory milestones in a pre-clinical phase. Notogen is now in discussion with the FDA with respect to an initial human clinical trial.